aurobindo pharma's arm recalls 2 antibiotic injections from us
.
.
.
"to be honest, that was what i had almost expected," she said.
.
eptinezumab is in phase iii trials. its maker plans to submit an application with the fda later this year. it is for chronic migraine prevention.
. however, bentley also warned that these treatments can be hazardous as they may cause bleeding which becomes more likely as the amount of svd increases.
.